EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative

Rowan T Chlebowski iD, Aaron K Aragaki, Kathy Pan, Michael S Simon iD, Marian L Neuhouser, Reina Haque iD, Thomas E Rohan, Jean Wactawski-Wende, Tonya S Orchard iD, Joanne E Mortimer iD, Dorothy Lane, Andrew M Kaunitz und 4 weitere

Cancer · 15.09.2024 · 130 (18) · 3147-3156

DOI: 10.1002/cncr.35318 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, online erschienen am 13.05.2024. Verfasst von Rowan T Chlebowski und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Lundquist Institute, Torrance, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Metabolic Syndrome, Obesity, Postmenopause. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the Women’s Health Initiative (WHI) randomized trial, dietary intervention significantly reduced breast cancer mortality, especially in women with more metabolic syndrome (MetS) components. Therefore, this study investigated the associations of MetS and obesity with postmenopausal breast cancer after long‐term follow‐up in the WHI clinical trials.

Methods

A total of 68,132 postmenopausal women, without prior breast cancer and with normal mammogram, were entered into WHI randomized clinical trials; 63,330 women with an entry MetS score comprised the study population. At entry, body mass index (BMI) was determined; MetS score (0, 1–2, and 3–4) included the following: (1) high waist circumference (≥88 cm), (2) high blood pressure (systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg, or hypertension history), (3) high‐cholesterol history, and (4) diabetes history. Study outcomes included breast cancer incidence, breast cancer mortality, deaths after breast cancer, and results by hormone receptor status.

Results

After a >20‐year mortality follow‐up, a higher MetS score (3–4), adjusted for BMI, was significantly associated with more poor prognosis, estrogen receptor (ER)–positive, progesterone receptor (PR)–negative cancers ( p = .03), 53% more deaths after breast cancer ( p < .001), and 44% higher breast cancer mortality ( p = .03). Obesity status, adjusted for MetS score, was significantly associated with more good prognosis, ER‐positive, PR‐positive cancers ( p < .001), more total breast cancers ( p < .001), and more deaths after breast cancer ( p < .001), with higher breast cancer mortality only in women with severe obesity (BMI, ≥35 kg/m 2 ; p < .001).

Conclusions

MetS and obesity status have independent, but differential, adverse associations with breast cancer receptor subtypes and breast cancer mortality risk. Both represent separate targets for breast cancer prediction and prevention strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMetabolic SyndromeObesityPostmenopauseBody Mass IndexHumansFemaleMiddle AgedIncidenceAgedWomen's HealthRisk Factors

Stichwörter der Autor:innen

Women's Health Initiativebreast cancerdiabetesmetabolic syndromeobesitywaist circumference

Autor:innen und Institutionen

  • The Lundquist Institute, Torrance, California, USA.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Kaiser Permanente Southern California, Downey, California, USA.
  • Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
  • Department of Health Systems Science, Department of Research & Evaluation, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.

ORCID-Profile: Rowan T Chlebowski, Michael S Simon, Reina Haque, Tonya S Orchard, Joanne E Mortimer

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Chlebowski, R. T., Aragaki, A. K., Pan, K., Simon, M. S., Neuhouser, M. L., Haque, R., Rohan, T. E., Wactawski-Wende, J., Orchard, T. S., Mortimer, J. E., Lane, D., Kaunitz, A. M., Desai, P., Wild, R. A., Barac, A., & Manson, J. E. (2024). Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative. Cancer, 130(18), 3147-3156. https://doi.org/10.1002/cncr.35318

Vancouver

Chlebowski RT, Aragaki AK, Pan K, Simon MS, Neuhouser ML, Haque R, et al. Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative. Cancer. 2024;130(18):3147-3156. doi:10.1002/cncr.35318

BibTeX
@article{Chlebowski2024,
  author = {Chlebowski, Rowan T and Aragaki, Aaron K and Pan, Kathy and Simon, Michael S and Neuhouser, Marian L and Haque, Reina and Rohan, Thomas E and Wactawski-Wende, Jean and Orchard, Tonya S and Mortimer, Joanne E and Lane, Dorothy and Kaunitz, Andrew M and Desai, Pinkal and Wild, Robert A and Barac, Ana and Manson, JoAnn E},
  title = {Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {18},
  pages = {3147--3156},
  doi = {10.1002/cncr.35318}
}
Kostenlos starten →